Opioid, antipsychotic and hypnotic use in end of life in long-term care facilities in six European countries: results of PACE.


Journal

European journal of public health
ISSN: 1464-360X
Titre abrégé: Eur J Public Health
Pays: England
ID NLM: 9204966

Informations de publication

Date de publication:
01 02 2019
Historique:
pubmed: 5 10 2018
medline: 23 7 2019
entrez: 5 10 2018
Statut: ppublish

Résumé

Opioids, antipsychotics and hypnotics are recommended for comfort care in dying. We studied their prescription during the last 3 days in residents deceased in the long-term care facility (LTCF). In a retrospective, cross-sectional survey in Belgium, England, Finland, Italy, the Netherlands and Poland, LTCFs, selected by proportional stratified random sampling, reported all deaths over the previous 3 months. The nurse most involved in the residents' care reviewed the chart for opioid, antipsychotic and hypnotic prescription, cause of death and comorbidities. Multivariable logistic regression was performed to adjust for resident characteristics. Response rate was 81.6%. We included 1079 deceased residents in 322 LCTFs. Opioid prescription ranged from 18.5% (95% CI: 13.0-25.8) of residents in Poland to 77.9% (95% CI: 69.5-84.5) in the Netherlands, antipsychotic prescription from 4.8% (95% CI: 2.4-9.1) in Finland to 22.4% (95% CI: 14.7-32.4) in Italy, hypnotic prescription from 7.8% (95% CI: 4.6-12.8) in Finland to 47.9% (95% CI: 38.5-57.3) in the Netherlands. Differences in opioid, antipsychotic and hypnotic prescription between countries remained significant (P < 0.001) when controlling for age, gender, length of stay, cognitive status, cause of death in multilevel, multivariable analyses. Dying from cancer showed higher odds for receiving opioids (OR 3.51; P < 0.001) and hypnotics (OR 2.10; P = 0.010). Opioid, antipsychotic and hypnotic prescription in the dying phase differed significantly between six European countries. Further research should determine the appropriateness of their prescription and refine guidelines especially for LTCF residents dying of non-cancer diseases.

Sections du résumé

Background
Opioids, antipsychotics and hypnotics are recommended for comfort care in dying. We studied their prescription during the last 3 days in residents deceased in the long-term care facility (LTCF).
Methods
In a retrospective, cross-sectional survey in Belgium, England, Finland, Italy, the Netherlands and Poland, LTCFs, selected by proportional stratified random sampling, reported all deaths over the previous 3 months. The nurse most involved in the residents' care reviewed the chart for opioid, antipsychotic and hypnotic prescription, cause of death and comorbidities. Multivariable logistic regression was performed to adjust for resident characteristics.
Results
Response rate was 81.6%. We included 1079 deceased residents in 322 LCTFs. Opioid prescription ranged from 18.5% (95% CI: 13.0-25.8) of residents in Poland to 77.9% (95% CI: 69.5-84.5) in the Netherlands, antipsychotic prescription from 4.8% (95% CI: 2.4-9.1) in Finland to 22.4% (95% CI: 14.7-32.4) in Italy, hypnotic prescription from 7.8% (95% CI: 4.6-12.8) in Finland to 47.9% (95% CI: 38.5-57.3) in the Netherlands. Differences in opioid, antipsychotic and hypnotic prescription between countries remained significant (P < 0.001) when controlling for age, gender, length of stay, cognitive status, cause of death in multilevel, multivariable analyses. Dying from cancer showed higher odds for receiving opioids (OR 3.51; P < 0.001) and hypnotics (OR 2.10; P = 0.010).
Conclusions
Opioid, antipsychotic and hypnotic prescription in the dying phase differed significantly between six European countries. Further research should determine the appropriateness of their prescription and refine guidelines especially for LTCF residents dying of non-cancer diseases.

Identifiants

pubmed: 30285189
pii: 5115229
doi: 10.1093/eurpub/cky196
pmc: PMC6345144
doi:

Substances chimiques

Analgesics, Opioid 0
Antipsychotic Agents 0
Hypnotics and Sedatives 0

Types de publication

Comparative Study Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

74-79

Références

Age Ageing. 2016 Jan;45(1):54-60
pubmed: 26764395
Z Gerontol Geriatr. 2015 Feb;48(2):176-83
pubmed: 25119700
J Pain Symptom Manage. 2014 Apr;47(4):710-20
pubmed: 23916680
BMC Geriatr. 2011 Jul 14;11:35
pubmed: 21752299
Drugs Aging. 2011 Apr 1;28(4):283-93
pubmed: 21428463
J Am Med Dir Assoc. 2016 Jun 1;17(6):566.e1-7
pubmed: 27161314
Minerva Anestesiol. 2010 Dec;76(12):1060-71
pubmed: 20634788
Support Care Cancer. 2017 May;25(5):1615-1620
pubmed: 28097432
J Am Geriatr Soc. 2017 Feb;65(2):286-293
pubmed: 28198563
J Am Med Dir Assoc. 2015 Jun 1;16(6):475-81
pubmed: 25736822
World J Clin Cases. 2017 Mar 16;5(3):73-81
pubmed: 28352631
J Palliat Med. 2013 Jan;16(1):31-7
pubmed: 23234299
BMC Med. 2017 May 18;15(1):102
pubmed: 28514961
Curr Alzheimer Res. 2017;14(5):512-522
pubmed: 27357646
J Med Toxicol. 2012 Dec;8(4):417-23
pubmed: 22983893
BMC Geriatr. 2014 Sep 02;14:99
pubmed: 25181947
J Pain Symptom Manage. 2012 Nov;44(5):681-91
pubmed: 22765968
Clin Interv Aging. 2016 Mar 21;11:335-40
pubmed: 27051281
J Am Med Dir Assoc. 2015 Nov 1;16(11):973-8
pubmed: 26170037
Eur Neuropsychopharmacol. 2014 Jan;24(1):95-104
pubmed: 24126116
Alzheimers Dement. 2015 Jun;11(6):691-9
pubmed: 25239738
Scand J Prim Health Care. 2014 Dec;32(4):187-92
pubmed: 25363144
J Pain Symptom Manage. 2014 Oct;48(4):649-59.e1
pubmed: 24703944
Pain. 2010 Jan;148(1):70-4
pubmed: 19910119
Pain. 2010 May;149(2):345-53
pubmed: 20334974
Clin Med (Lond). 2016 Jun;16(3):254-8
pubmed: 27251915
J Pain Symptom Manage. 2014 Feb;47(2):283-97
pubmed: 23870413
Alzheimer Dis Assoc Disord. 1997 Jun;11(2):71-7
pubmed: 9194953
J Palliat Med. 2013 Jan;16(1):38-43
pubmed: 23234300

Auteurs

Marc Tanghe (M)

End-of-Life Care Research Group, Ghent University, Ghent, Belgium.

Nele Van Den Noortgate (N)

Department of Geriatrics, Ghent University Hospital, Ghent, Belgium.

Lara Pivodic (L)

End-of-Life Care Research Group, Vrije Universiteit Brussel, Brussels, Belgium.

Luc Deliens (L)

End-of-Life Care Research Group, Vrije Universiteit Brussel, Brussels, Belgium.

Bregje Onwuteaka-Philipsen (B)

Medisch Centrum, Vrije Universiteit, Amsterdam, The Netherlands.

Katarzyna Szczerbinska (K)

Jagiellonian University Medical College, Kraków, Poland.

Harriet Finne-Soveri (H)

National Institute for Health and Welfare, Helsinki, Finland.

Danni Collingridge-Moore (D)

Lancaster University, Lancaster, UK.

Giovanni Gambassi (G)

Fondazione Policlinico Universitario A. Gemelli, IRCCS and Università Cattolica del Sacro Cuore, Roma, Italy.

Lieve Van den Block (L)

End-of-Life Care Research Group, Vrije Universiteit Brussel, Brussels, Belgium.

Ruth Piers (R)

Department of Geriatrics, Ghent University Hospital, Ghent, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH